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Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the
chimeric protein p210 BCR-ABL. The tumor suppressor PTEN plays a critical role in the pathogenesis of CML chronic phase,
through non genomic loss of function mechanisms, such as protein down-regulation and impaired nuclear/cytoplasmic
shuttling. Here we demonstrate that BCR-ABL promotes PTEN downregulation through a MEK dependent pathway.
Furthermore, we describe a novel not recurrent N212D-PTEN point mutation found in the EM2 blast crisis cell line.
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Introduction
The tumor suppressor PTEN is one of the mostly mutated
tumor suppressors in cancer [1]. PTEN acts as a phosphatase that
dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3),
the lipid product of the class I phosphoinositide 3-kinases (PI3K).
PTEN inactivation by point mutations or deletion aberrantly
activates PI3K–AKT pathway, promoting cell growth, survival
and proliferation. Beside canonical genetic loss of function, PTEN
tumor suppressive functions could be impaired by non genomic
mechanisms, such as epigenetic silencing of PTEN, post-
transcriptional regulation by non-coding RNAs and post-transla-
tional modifications [2,3]. In particular, deregulation of PTEN
protein levels by non-coding RNAs and impaired proper nuclear-
cytoplasmic shuttling by mono-ubiquitination have extensively
been reported to impair its tumor suppressive functions [1,4].
Chronic Myeloid Leukemia is a myeloproliferative disorder
characterized by the translocation t(9;22), coding for the chimeric
protein BCR-ABL [5,6]. PTEN has been shown to play a critical
role in the pathogenesis of Chronic Myeloid Leukemia (CML),
through both protein down-regulation and impaired nuclear/
cytoplasmic shuttling by mono-ubiquitination [7,8]. Expression of
BCR-ABL was associated with the reduction of PTEN levels
although the mechanism of PTEN expression regulation was not
reported [9,10]. The relevance of the BCR-ABL-induced PTEN
downregulation and delocalization could have dramatic implica-
tions from the therapeutic standpoint. The identification of the
mechanisms that promote BCR-ABL-induced PTEN downregu-
lation and delocalization could indeed be targetable and therefore
leading to the reactivation of the tumor suppressor with dramatic
consequences.
Results and Discussion
To better investigate the regulation of PTEN expression levels
by BCR-ABL, we have transfected BCR-ABL in NIH3T3 cells
and we have measured PTEN levels by western immunoblot. As
observed in Figure 1A, similarly to what described elsewhere
[9,10], BCR-ABL expression is associated with the downregula-
tion of PTEN expression, which appears to be transcriptionally
mediated (Figure 1B). Similar observations were obtained in the
BCR-ABL expressing 32D cell line (data not shown and [9]). CML
primary CD34 positive cells also expressed lower levels of PTEN
compared to normal bone marrow CD34 positive cells (Fig-
ure 1C).
The observation that BCR-ABL downregulates PTEN levels
suggested that BCR-ABL could control those pathways that have
already be linked to the regulation of PTEN protein expression.
Oncogenic Ras-val12 promotes PTEN downregulation through a
MEK-Jun pathway [11]. Due to the relevance of Ras-MEK
pathway in the signaling transduction by BCR-ABL, we tested
whether treatment with MEK inhibitor UO126 could rescue
PTEN levels of expression. As shown in Figure 1D, UO126
restores normal PTEN levels in BCR-ABL expressing cells.
Interestingly, proteosome inhibitor MG132 is also associated with
a slight increase of PTEN levels. The observation that MEK
inhibitors upregulate PTEN levels could contribute to explain the
original observation that MEK inhibitors in association with TKI
are effective in promoting CML stem cell apoptosis [12].
All together these data further attribute to PTEN the role of
tumor suppressor in human CML. Due to the nature of CML as a
multiphase disease that can eventually evolve into a blast crisis, we
speculate that PTEN could be deleted or mutated during the
progression of the disease. It was already shown that in 5 cases of
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Figure 1. BCR-ABL downregulates PTEN expression. A) Left panel: evaluation of PTEN levels of expression in BCR-ABL-pcDNA3.1 transfected
NIH3T3. Right panel: quantification of PTEN levels. B) PTEN mRNA levels in BCR-ABL transfected NIH3T3 cells. C) Left panel: PTEN levels by western
immunoblot in primary CD34 positive cells obtained from the bone marrow of normal individuals and Chronic Myeloid Leukemia patients. Right
panel: quantification of PTEN levels. D) Stably expressing pBabe-BCR-ABL infected NIH3T3 cells were treated with MG132 and UO126 for 8 hours.
Control: parental NIH3T3 expressing pBABE-empty vector.
doi:10.1371/journal.pone.0110682.g001
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chronic phase CML and in 5 cases of CML blast phases PTEN
maintained the wild-type status [13]. We additionally analyzed 5
chronic phase and two blast phases CML patients but we did not
observed any PTEN mutations. To further extend this analysis, we
assessed the expression of PTEN in four CML blast crisis cell lines
(K562, LAMA, CML-T1 and EM2) by western immunoblot. All
these cell lines expressed PTEN although at different levels
(Figure 2A).
Figure 2. PTEN in CML blast crisis. A) PTEN protein levels in CML blast crisis. Jurkat cell line was used as a PTEN null cell line. B) Chromatogram
from sanger sequencing analysis of PTEN in the EM2 cell line. C) Schematic representation of PTEN. D) Left: evaluation by western immunoblot of
myc-tagged-PTEN-N212D point mutation expression after transfection of myc-tag-PTEN-WT and N212D plasmid in 292HEK cell line. Right:
quantification of PTEN levels.
doi:10.1371/journal.pone.0110682.g002
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Next, we assessed PTEN mutational status in the four CML
blast crisis cell lines, by sequencing all the exons as reported
elsewhere [14]. With this approach, we identified a PTEN N212D
point mutation in the EM2 blast crisis, as reported in Figure 2B.
PTEN N212D is located inside the C2 domain of PTEN, which is
involved in the binding of phospholipid and in the regulation of
PTEN protein stability (Figure 2C) [15]. To assess the effects of
N212D mutation on PTEN stability, we generated PTEN N212D
mutant in pRK5-myc-tagged-PTEN vector by site direct muta-
genesis, as reported previously [8]. Expression of PTEN N212D
mutant construct in 293HEK cells revealed that this mutation
renders PTEN unstable with a consequent marked reduction of its
expression (Figure 2D and 2E). In conclusion, we propose that
PTEN is mostly involved in the pathogenesis of the chronic phase
of CML through non genomic loss of function. In particular,
BCR-ABL itself is able to promote both PTEN downregulation
and delocalization with the loss of its tumor suppressive function
[7,8]. Progression of CML into blast phase does not seem to be
associated with PTEN point mutations that genetically cause
complete PTEN inactivation. Additional analyses using highly
sensitive next generation sequencing approaches are mandatory to
assess PTEN mutational status during the CML progression into
blast phase in bigger cohorts of patients.
Materials and Methods
Cell line and reagents
NIH3T3, 293HEK, Jurkat, K562, CML-T1, LAMA and EM2
cell line were purchased from ATCC. Myc-tagged pRK5-PTEN,
p210-BCR-ABL pcDNA3.1 and p210-BCR-ABL-pBABE plas-
mids, myc-tag antibody, anti Tubulin antibody and mutagenesis
strategy were described elsewhere [8]. Similarly, transfections and
infections were performed as previously described [8].
Western immunoblot
Cells were lysate and treated as described elsewhere [8].
PTEN sequences
PTEN sequencing analysis has been performed as described
elsewhere [14].
CML primary cells
CML primary cells were collected at the moment of diagnosis
from 4 patients upon informed consent. Cells were separated to
obtain Lin2CD34+CD38+ and Lin+ cells as previously reported
[8]. This project was reviewed and approved by the San Luigi
Hospital Institutional Ethical Committee (Code # 10/2013).
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